Fig. 1
From: Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice
The effect of PEG-FGF21 and FGF21 on blood glucose and plasma insulin in DIO mice. FGF21 and PEG-FGF21 treatment protocol for diabetic mice wherein diabetic mice received vehicle or FGF21 and PEG-FGF21 (25 μg/kg BW, every other three days) for 10 weeks (a). Random-fed blood glucose (b) and plasma insulin levels (c). During chronic treatment of DIO mice with FGF21 and PEG-FGF21. Insulin resistance (IR) measured in DIO mice after 2 months of FGF21 and PEG-FGF21 treatment. IR = FINS * FBG/22.5 (d). Ad libitum fed mice were injected subcutaneously with 25ug/kg of FGF21, PEG-FGF21 or control vehicle (PBS) every 72 h. Values are means ± SEM. Statistics by two-tailed t-test: *P ≤ 0.05; vs DIO + FGF21.n = 10